Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 6
2004 3
2005 4
2006 4
2007 4
2008 6
2009 6
2010 6
2011 7
2012 11
2013 6
2014 14
2015 12
2016 21
2017 19
2018 12
2019 12
2020 18
2021 16
2022 18
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Results by year

Filters applied: . Clear all
Page 1
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.
Puszkiel A, Bianconi G, Pasquiers B, Balakirouchenane D, Arrondeau J, Boudou-Rouquette P, Bretagne MC, Salem JE, Declèves X, Vidal M, Kramkimel N, Guegan S, Aractingi S, Huillard O, Alexandre J, Wislez M, Goldwasser F, Blanchet B. Puszkiel A, et al. Among authors: wislez m. Br J Cancer. 2024 Mar 26. doi: 10.1038/s41416-024-02659-x. Online ahead of print. Br J Cancer. 2024. PMID: 38532102
Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).
Auliac JB, Thomas PA, Bylicki O, Guisier F, Curcio H, AlainVegnenègre, Swalduz A, Wislez M, Le Treut J, Decroisette C, Basse V, Falchero L, De Chabot G, Moreau D, Huchot E, Lupo Mansuet A, Blons H, Chouaïd C, Greillier L. Auliac JB, et al. Among authors: wislez m. Ther Adv Med Oncol. 2024 Mar 6;16:17588359241236451. doi: 10.1177/17588359241236451. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38455711 Free PMC article.
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Baptiste Oudart J, Garinet S, Leger C, Barlesi F, Mazières J, Jeannin G, Audigier-Valette C, Morot-Sibilot D, Langlais A, Amour E, Mathiot N, Birsen G, Blons H, Wislez M. Baptiste Oudart J, et al. Among authors: wislez m. Lung Cancer. 2024 Apr;190:107508. doi: 10.1016/j.lungcan.2024.107508. Epub 2024 Feb 19. Lung Cancer. 2024. PMID: 38428265 Free article. Clinical Trial.
[A 2023 inventory in oncology news].
Bay JO, Auberger B, Bouleuc C, Cohen R, Delom F, Firmin N, Gandemer V, L'Allemain G, Magne N, De Nonneville A, Orbach D, Pellier I, Rodrigues M, Wislez M; pour le comité de rédaction du Bulletin du Cancer. Bay JO, et al. Among authors: wislez m. Bull Cancer. 2024 Jan;111(1):18-32. doi: 10.1016/j.bulcan.2023.12.003. Epub 2024 Jan 5. Bull Cancer. 2024. PMID: 38184423 Review. French.
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations.
Christopoulos P, Girard N, Proto C, Soares M, Lopez PG, van der Wekken AJ, Popat S, Diels J, Schioppa CA, Sermon J, Rahhali N, Pick-Lauer C, Adamczyk A, Penton J, Wislez M. Christopoulos P, et al. Among authors: wislez m. Cancers (Basel). 2023 Nov 8;15(22):5326. doi: 10.3390/cancers15225326. Cancers (Basel). 2023. PMID: 38001589 Free PMC article.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Clinical Trial.
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).
Dehem A, Mazieres J, Chour A, Guisier F, Ferreira M, Boussageon M, Girard N, Moro-Sibilot D, Cadranel J, Zalcman G, Ricordel C, Wislez M, Munck C, Poulet C, Gauvain C, Descarpentries C, Wasielewski E, Cortot AB, Baldacci S. Dehem A, et al. Among authors: wislez m. Lung Cancer. 2023 Dec;186:107393. doi: 10.1016/j.lungcan.2023.107393. Epub 2023 Oct 9. Lung Cancer. 2023. PMID: 37839252
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Impact of sarcopenia indexes on survival and severe immune acute toxicity in metastatic non-small cell lung cancer patients treated with PD-1 immune checkpoint inhibitors.
Ashton E, Arrondeau J, Jouinot A, Boudou-Rouquette P, Hirsch L, Huillard O, Ulmann G, Lupo-Mansuet A, Damotte D, Wislez M, Alifano M, Alexandre J, Goldwasser F. Ashton E, et al. Among authors: wislez m. Clin Nutr. 2023 Jun;42(6):944-953. doi: 10.1016/j.clnu.2023.03.023. Epub 2023 Apr 14. Clin Nutr. 2023. PMID: 37099986
198 results